Natalie McCarty
Family · Grand Rapids, MINPI 1679042733
Payments from drug & device makers
Across 101 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$145
- GSK$141
- AstraZeneca$135
- Merck$132
- Incyte Corporation$127
- Seagen Inc.$126
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,06699%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $145 |
| GSK | 2 | $141 |
| AstraZeneca(2 entities) | 6 | $135 |
| Merck | 5 | $132 |
| Incyte Corporation | 7 | $127 |
| Seagen Inc. | 8 | $126 |
| Ipsen Biopharmaceuticals, Inc | 5 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $114 |
| Pfizer | 7 | $114 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $104 |
| Gilead | 5 | $87 |
| Sanofi | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $72 |
| Genentech USA, Inc. | 3 | $58 |
| Taiho Oncology, Inc. | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Stemline Therapeutics Inc. | 1 | $36 |
| Karyopharm Therapeutics Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $35 |
| Amgen | 2 | $33 |
| Bayer | 2 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| G1 Therapeutics, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Exelixis Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| AbbVie | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $14 |
| Myovant Sciences Inc. | 1 | $13 |
| Servier Pharmaceuticals LLC | 1 | $13 |
| Foundation Medicine, Inc. | 1 | $13 |
| ADC Therapeutics America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLENREP$122
How this compares
$2,091 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 15 | $3,604 |
| Anastrozole | 64 | $1,744 |
| Letrozole | 18 | $1,021 |
| Tamoxifen Citrate | 13 | $697 |
Paid to pharmacies, not to this prescriber.
Other family in Grand Rapids
- Kelsey PrinceGrand Rapids$87K
- Marlee BogemaGrand Rapids$15K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.